Drug Profile

KFRX 04

Alternative Names: BK 40197; BK 40197 HCl; KFRX-04

Latest Information Update: 09 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator KeifeRx
Class Antidementias; Antineoplastics; Skin disorder therapies; Small molecules
Mechanism of Action Protein tyrosine kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Preclinical Amyotrophic lateral sclerosis; Mastocytosis; Mild cognitive impairment; Urticaria

09 Sep 2024 Preclinical trials in Amyotrophic lateral sclerosis in USA (PO) prior to September 2024 (Keiferx pipeline, September 2024)
29 Mar 2023 Preclinical trials in Mastocytosis in USA (PO) (keiferx pipeline, March 2023)
29 Mar 2023 Preclinical trials in Mild cognitive impairment in USA (PO) (keiferx pipeline, March 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com